No Popup.
Celltrion Healthcare
We have been contributing to the improvement of patient welfare and access to healthcare by offering innovative biologics to the world.
BUSINESSWe are exerting efforts to achieve sustainable growth.
Celltrion Healthcare will shape a healthier and happier future for humanity by offering high-quality biologics.
Celltrion Healthcare offers biologics to about 110 countries, along with more than 30 global partners around the world. With hands-on experience and knowledge accumulated through years of working in the advanced pharmaceutical markets of the United States and Europe, Celltrion Healthcare has been securing distribution channels and providing patients with biosimilars at affordable prices.
PRODUCTS
Remsima®
Remsima® is a biosimilar infliximab approved by the European Medicines Agency (EMA) in August 2013 and the U.S. Food and Drug Administration (FDA) in April 2016. It is indicated for the treatment of Rheumatoid Arthritis(RA), Ankylosing Spondylitis(AS), Ulcerative Colitis(UC), Crohn’s disease(CD), Psoriatic Arthritis(PsA), and Psoriasis.
The world’s first biosimilar
monoclonal antibody
PRODUCTS
Truxima®
Truxima® is a biosimilar rituximab approved by the European Medicines Agency (EMA) in February 2017 and the U.S. Food and Drug Administration (FDA) in November 2018. It is indicated for the treatment of Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), and Rheumatoid Arthritis(RA).
The world’s first biosimilar
anticancer antibody
PRODUCTS
Herzuma®
Herzuma® is a biosimilar trastuzumab approved by the European Medicines Agency (EMA) in February 2018 and the U.S. Food and Drug Administration (FDA) in December 2018. It is indicated for the treatment of HER2-Positive Metastatic Breast Cancer, Early Breast Cancer(EBC), and Metastatic Gastric Cancer(MGC).
Biosimilar anticancer antibody
PRODUCTS
Remsima®SC
Remsima®SC is a SC formulation of biosimilar infliximab approved by the European Medicines Agency (EMA) in November 2019. It is indicated for the treatment of Rheumatoid Arthritis(RA), Crohn’s disease(CD), Ulcerative Colitis(UC), Ankylosing Spondylitis(AS), Psoriatic Arthritis(PsA), Psoriasis in adult patients.
The world's first subcutaneous
infliximab biosimilar
-
Celltrion USA Announces U.S. FDA Approval of Yuflyma® (adalimumab-aaty), a High-Concentration and Citrate-Free Formulation of Humira® (adalimumab) Biosimilar
더 알아보기
-
Celltrion Healthcare Launches IBD Awareness Campaign in Collaboration With Leading Patient Organisation, EFCCA, for World IBD Day 2023
더 알아보기
-
Celltrion Healthcare Presents Efficacy and Safety Data From Global Phase III LIBERTY Trial, at the 18th ECCO Congress
더 알아보기
-
Celltrion USA Appoints Thomas Nusbickel as Chief Commercial Officer
더 알아보기
GLOBAL NETWORKS
Global biologics
leading company
Celltrion Healthcare has become the world’s leading company that specializes in biologics by offering high-quality biosimilars to about 110 countries, with the ultimate goal of promoting the welfare of humanity.
